<b>The RESPONDER trial:</b> a feasibility study of an early intervention model deploying community first responders to administer intranasal naloxone in suspected opioid overdoses in Skåne, Sweden.

BMJ Open · 2026 · PMC13311636 · PMID 42365998

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

A decreasing trend in fatal overdoses was observed, but it was significant only among men. 11 Nasal naloxone was from March 2024 available for adults to purchase without prescription at Swedish pharmacies. 36 Prior international reports have addressed challenges with prescription-free naloxone in terms of cost and stigma. 37 38 The implementation in Sweden is yet to be evaluated.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

&lt;b&gt;The RESPONDER trial:&lt;/b&gt; a feasibility study of an early intervention model deploying community first responders to administer intranasal naloxone in suspected opioid overdoses in Skåne, Sweden.

The sentences

<b>The RESPONDER trial:</b> a feasibility study of an early intervention model deploying community first responders to administer intranasal naloxone in suspected opioid overdoses in Skåne, Sweden.